EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Potential utility of comprehensive genomic profiling to predict venous thromboembolism in patients with solid cancer

Kanna Nakamura, Kazuhisa Kaneda, Shinya Ikeda, Yugo Yamashita, Tomohiro Kondo, Shigemi Matsumoto, Hideaki Inazumi, Takahiko Kanamori, Takahiro Horie, Manabu Muto, Koh Ono

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.02.019 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Kanna Nakamura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Genomics, Gene Expression Profiling. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Heart Foundation, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: It has become increasingly important to accurately identify cancer patients at high risk for venous thromboembolism (VTE) who could have greater benefit with anticoagulants. Cancer-associated genomic variants could have a potential clinical utility for prediction of VTE. METHODS: This study was a single-center observational study using the C-CAT database, the national datacenter for cancer genomic medicine in Japan, and evaluated 412 cancer patients who underwent comprehensive genome profiling with FoundationOne CDx at Kyoto University Hospital. We comprehensively investigated the association between cancer-associated genomic variants and VTE development. RESULTS: In the entire cohort, 77% had distant metastasis, and 90% were under chemotherapy. During a median follow-up period of 693 days, 59 patients (14.3%) developed VTE events. The cumulative incidence of VTE events after specimen collection was 26.0% at 5 years. In the multivariable Fine-Gray sub-distribution hazard models adjusted for age, sex, cancer type, metastasis, and chemotherapy at baseline, several genomic variants showed a trend toward an increased risk of VTE, including ERBB2 (HR 2.43, 95% CI 1.21-4.87), APC (HR 1.94, 95% CI 0.84-4.50), KRAS (HR 1.67, 95% CI 0.79-3.53), ATM (HR 1.64, 95% CI 0.74-3.65), and NOTCH1 (HR 1.51, 95% CI 0.73-3.11). However, no variants remained statistically significant after correction for multiple testing. CONCLUSION: The current exploratory study identified several genomic variants potentially associated with a high risk of cancer-associated VTE, which may indicate potential clinical utility of comprehensive genomic profiling for accurate prediction of VTE events in cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsGenomicsGene Expression ProfilingBiomarkers, TumorHumansFemaleMaleRisk FactorsMiddle AgedAgedGenetic Predisposition to DiseasePredictive Value of TestsJapanRisk AssessmentIncidenceTime FactorsDatabases, FactualGenetic Risk ScoreAdultProportional Hazards ModelsPhenotypeAnticoagulantsGenetic Variation

Stichwörter der Autor:innen

cancercardio-oncologygenome profilingpredictionvenous thromboembolism

Substanzen

AnticoagulantsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Pharmacology, Shiga University of Medical Science, Otsu, Japan.
  • Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: yyamashi@kuhp.kyoto-u.ac.jp.
  • Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan; Department of Real-World Data R&D, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Japan Heart Foundation
  • Takeda Science Foundation

Zitieren

APA

Nakamura, K., Kaneda, K., Ikeda, S., Yamashita, Y., Kondo, T., Matsumoto, S., Inazumi, H., Kanamori, T., Horie, T., Muto, M., & Ono, K. (2026). Potential utility of comprehensive genomic profiling to predict venous thromboembolism in patients with solid cancer. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.02.019

Vancouver

Nakamura K, Kaneda K, Ikeda S, Yamashita Y, Kondo T, Matsumoto S, et al. Potential utility of comprehensive genomic profiling to predict venous thromboembolism in patients with solid cancer. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.02.019

BibTeX
@article{Nakamura2026,
  author = {Nakamura, Kanna and Kaneda, Kazuhisa and Ikeda, Shinya and Yamashita, Yugo and Kondo, Tomohiro and Matsumoto, Shigemi and Inazumi, Hideaki and Kanamori, Takahiko and Horie, Takahiro and Muto, Manabu and Ono, Koh},
  title = {Potential utility of comprehensive genomic profiling to predict venous thromboembolism in patients with solid cancer},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.02.019}
}
Kostenlos starten →